HUE033274T2 - Vegyületek és BACE-gátlóként történõ alkalmazásuk - Google Patents

Vegyületek és BACE-gátlóként történõ alkalmazásuk Download PDF

Info

Publication number
HUE033274T2
HUE033274T2 HUE11850232A HUE11850232A HUE033274T2 HU E033274 T2 HUE033274 T2 HU E033274T2 HU E11850232 A HUE11850232 A HU E11850232A HU E11850232 A HUE11850232 A HU E11850232A HU E033274 T2 HUE033274 T2 HU E033274T2
Authority
HU
Hungary
Prior art keywords
mmol
mixture
added
compound
bromo
Prior art date
Application number
HUE11850232A
Other languages
English (en)
Inventor
Gabor Csjernyik
Sofia Karlstroem
Annika Kers
Karin Kolmodin
Martin Nyloef
Liselotte Oehberg
Laszlo Rakos
Lars Sandberg
Fernando Sehgelmeble
Peter Soederman
Britt-Marie Swahn
Berg Stefan Von
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46314249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE033274(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HUE033274T2 publication Critical patent/HUE033274T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Claims (2)

  1. 'Szahasaimi igényganíök
    1. Vagyöfeí, amsty as < 1 r, 1 ; ^I R:-'í-naSöxs'-ö:>'-fnsiíi ; -6" 1 S~(prop -1 -1 ri' 1 -·ΐä>piíí<sin - 3 - j?|-3^i - däs ρíroCGm^hexstn·' 1 ,:2'Ίη0όη·'ΐ t2’Mmíds2öjH"-amtó
    vtgy gyögpsnarészatiisg -^fogadható sója. 2. ©yóg.yszarészeti készítmény, «tnaiy aktív alkotóként as 1, igénypont szerinti vágyóiét vagy gyógyszarészétiieg elfogadható sója gyógyászatijáig hatásos mennyiségét .tartalmazza; legalább egy gyógyszerésssiiirKí elfogadható segédanyaggal* hordozóval vagy hígiiószerrst agyölt 3. ás t. igénypont szerinti vagyaiét: vagy gyógyszerészeiiiisg elfogadható sója gyógyszerként történő aikaliY-azásia. 4 As 1 igénypont szerinti vegyidet vegy gyégyszerészetiieg elfogadható sója a következők kezelésére vagy megelőzésére szolgáló eljéréséan történő eiksknszäsra: áil-vel kapesoiatos pateiögiás állapét, ahol az Aihvai kapcsolatos patológiás éllepot Oawn szindróma. egy s>amiioid angsopáíla. agyi amilokt angiopétia, örökletes agyi vérzékenység, ssetteml ieépőléshez: Rapesolodó rendellenesség, MGs ("enyhe szellemi leépülésé} Atenaímer-kóh memöriavesziés, AisheimerAőrhoz társsáé égyaiernhiéhyos sizlmpiohfok, Aizheitoer-Rórhoz. íársoió neurorepneráció* vágyás érrendszeri eredetű demencia, degeneratfv eredetű dementia, pié-sssniiis demenöia, szenilis demanda,. Parkinson-Rórhoz társuló demands, progresszív szuprsnukleáris bénulás vagy kortikéiis bazélis degeneráció.
  2. 6, Vágyóiét 'zagy győgyezereszetiieg affogadhstó sóisr aifeaimazésra a 4, igénypont szedni, ahol az ASi-vai kapcsolatos patológiás áSlapot as Atzheimer-kor. §. Vsgyütet vagy gyógyszzerészetiieg elfogadható sója alkalmazásra a 4. vagy 5. igénypont szerint, ahol az alkalmazás kombinálva van Isgaiáob egy szellemi képességet javító szerrel, memóriát javító sserrei vagy kálim ászterézgáílóvm.
HUE11850232A 2010-12-22 2011-12-21 Vegyületek és BACE-gátlóként történõ alkalmazásuk HUE033274T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061425852P 2010-12-22 2010-12-22
US201161529620P 2011-08-31 2011-08-31

Publications (1)

Publication Number Publication Date
HUE033274T2 true HUE033274T2 (hu) 2017-11-28

Family

ID=46314249

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11850232A HUE033274T2 (hu) 2010-12-22 2011-12-21 Vegyületek és BACE-gátlóként történõ alkalmazásuk

Country Status (38)

Country Link
US (6) US8415483B2 (hu)
EP (2) EP2655378B1 (hu)
JP (3) JP6180325B2 (hu)
KR (1) KR101916975B1 (hu)
CN (2) CN103380133B (hu)
AR (1) AR084553A1 (hu)
AU (3) AU2011345389B2 (hu)
BR (1) BR112013016030B1 (hu)
CA (1) CA2822378C (hu)
CL (1) CL2013001849A1 (hu)
CO (1) CO6781485A2 (hu)
CR (1) CR20130308A (hu)
CY (1) CY1119211T1 (hu)
DK (1) DK2655378T3 (hu)
DO (3) DOP2013000147A (hu)
EA (2) EA032687B1 (hu)
EC (1) ECSP13012708A (hu)
ES (2) ES2780928T3 (hu)
GT (1) GT201300165A (hu)
HR (1) HRP20170723T1 (hu)
HU (1) HUE033274T2 (hu)
LT (1) LT2655378T (hu)
ME (1) ME02728B (hu)
MX (1) MX342477B (hu)
MY (1) MY178156A (hu)
NI (1) NI201300055A (hu)
NZ (2) NZ709235A (hu)
PE (2) PE20171342A1 (hu)
PL (1) PL2655378T3 (hu)
PT (1) PT2655378T (hu)
RS (1) RS55961B1 (hu)
SA (2) SA111330107B1 (hu)
SG (2) SG191127A1 (hu)
SI (1) SI2655378T1 (hu)
TW (2) TWI618700B (hu)
UY (1) UY33829A (hu)
WO (1) WO2012087237A1 (hu)
ZA (1) ZA201305495B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889703B2 (en) 2010-02-24 2014-11-18 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
EP2780321B1 (en) 2011-10-10 2015-12-30 Astrazeneca AB Mono-fluoro beta-secretase inhibitors
US8779355B2 (en) * 2011-12-28 2014-07-15 Quest Diagnostics Investments, Inc. Methods for detecting lacosamide by mass spectrometry
CA2856892C (en) 2012-01-26 2020-05-12 F. Hoffmann-La Roche Ag Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
AU2013267555A1 (en) 2012-05-30 2014-12-04 Comentis, Inc. Chromane compounds
US9000184B2 (en) * 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000185B2 (en) * 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000183B2 (en) * 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) * 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US10548882B2 (en) * 2012-06-21 2020-02-04 Astrazeneca Ab Camsylate salt
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
EP2900650A1 (en) * 2012-09-28 2015-08-05 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
DK2956443T3 (da) 2013-02-12 2020-01-20 Buck Inst Res Aging Hydantoiner som modulatorer af BACE-medieret APP-forarbejdning
TW201629025A (zh) 2014-10-07 2016-08-16 阿斯特捷利康公司 化合物及其作為ｂａｃｅ抑制劑之用途
AR107783A1 (es) 2016-03-15 2018-06-06 Lilly Co Eli Terapia de combinación
KR20180119670A (ko) 2016-03-15 2018-11-02 아스트라제네카 아베 아밀로이드 베타의 축적과 관련된 질환의 치료를 위한 bace 억제제와 항체 또는 항원 결합 단편의 조합
US20190084928A1 (en) * 2016-04-01 2019-03-21 National University Corporation Chiba University Method for producing nitrogen-containing aromatic amide, method for producing pyrrole-imidazole polyamide, and compound
CN107892697B (zh) 2016-12-26 2020-11-03 郑州泰基鸿诺医药股份有限公司 一种[1,3]噻嗪-2-胺类化合物及应用，药物组合物
CN107954927A (zh) * 2017-10-30 2018-04-24 广东莱佛士制药技术有限公司 一种3-溴-5-(丙炔-1-基)吡啶的制备方法
WO2019122268A1 (en) 2017-12-21 2019-06-27 Astrazeneca Ab Processes for the stereoselective preparation of bace inhibitors
WO2019122421A1 (en) 2017-12-22 2019-06-27 Astrazeneca Ab Stereoselective ketone reduction using a ketoreductase enzyme
WO2019129755A1 (en) 2017-12-29 2019-07-04 Astrazeneca Ab Ketal hydrogenation
WO2019129750A1 (en) 2017-12-29 2019-07-04 Astrazeneca Ab Processes for the racemization of dihydroimidazole ring systems
CN110615751B (zh) * 2018-06-19 2021-08-17 上海医药工业研究院 一种2-氧代硫代丙酰胺的制备方法
WO2020183021A1 (en) 2019-03-14 2020-09-17 Astrazeneca Ab Lanabecestat for weight loss
CN111253427A (zh) * 2020-03-13 2020-06-09 苏州大学 正丁基锂在催化醛和硅烷的氰硅化反应中的应用
CN114989103B (zh) * 2022-06-09 2024-07-09 杭州科巢生物科技有限公司 一种2-甲氧基-3-(1-甲基-1h-1,2,4-三唑-3-基)苯胺的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100452491B1 (ko) 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
JP4273406B2 (ja) * 2001-06-01 2009-06-03 小野薬品工業株式会社 アルドース還元酵素阻害剤を有効成分とする脱髄性疾患または脱髄を伴う疾患治療剤
US7592348B2 (en) * 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP1729771B1 (en) 2004-03-22 2009-10-14 Eli Lilly &amp; Company Pyridyl derivatives and their use as mglu5 receptor antagonists
TW201004961A (en) 2005-06-14 2010-02-01 Schering Corp Aspartyl protease inhibitors
CN101360716A (zh) 2005-11-21 2009-02-04 阿斯利康(瑞典)有限公司 新颖的2-氨基-咪唑-4-酮化合物及其在制备用于治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物中的用途
JP2009521488A (ja) 2005-12-21 2009-06-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｋｃ−シータのインヒビターとして有益なピリミジン誘導体
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
UA96598C2 (ru) * 2006-06-22 2011-11-25 Астразенека Аб Замещенные изоиндолы как ингибиторы васе и их применение
WO2008076044A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5, 5-diaryl-imidazol-4-ones
US20090325993A1 (en) * 2007-02-01 2009-12-31 Nadia Mamoona Ahmad GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders
EP2155737A1 (en) * 2007-05-07 2010-02-24 Schering Corporation Gamma secretase modulators
EP2249646A4 (en) 2008-02-06 2013-09-25 Glaxo Group Ltd PDE4 muscarinic Antagonist-DOPPELPHARMACOPHOREN
FR2929943B1 (fr) 2008-04-15 2010-09-24 Inst Rech Developpement Ird Sels de quinoleines 2-substituees
AU2009277485B2 (en) 2008-07-28 2013-05-02 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
US8450308B2 (en) 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
JP5579720B2 (ja) 2008-09-11 2014-08-27 アムジエン・インコーポレーテツド ベータ−セクレターゼ調節物質としてのスピロ四環式化合物および使用法
EP2801570A1 (en) 2009-03-13 2014-11-12 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
TW201105650A (en) 2009-07-02 2011-02-16 Astrazeneca Ab New compounds
AR077365A1 (es) 2009-07-02 2011-08-24 Astrazeneca Ab Derivados de imidazol para el tratamiento de enfermedades mediadas por la inhibicion de la formacion de abeta
US8889703B2 (en) 2010-02-24 2014-11-18 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US20120065195A1 (en) 2010-03-31 2012-03-15 Clark Christopher T Compounds for treating neurodegenerative diseases
WO2011130741A1 (en) 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
EP2601197B1 (en) 2010-08-05 2014-06-25 Amgen Inc. Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
TW201219400A (en) 2010-09-24 2012-05-16 Array Biopharma Inc Compounds for treating neurodegenerative diseases
TW201307357A (zh) 2010-11-22 2013-02-16 Array Biopharma Inc 治療神經退化性疾病之化合物
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
EP2780321B1 (en) 2011-10-10 2015-12-30 Astrazeneca AB Mono-fluoro beta-secretase inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US10548882B2 (en) 2012-06-21 2020-02-04 Astrazeneca Ab Camsylate salt

Also Published As

Publication number Publication date
WO2012087237A1 (en) 2012-06-28
CN106008355B (zh) 2019-05-03
US20180221367A1 (en) 2018-08-09
EP2655378A1 (en) 2013-10-30
LT2655378T (lt) 2017-06-12
JP2014504300A (ja) 2014-02-20
US20120165347A1 (en) 2012-06-28
JP6527255B2 (ja) 2019-06-05
RS55961B1 (sr) 2017-09-29
NZ612041A (en) 2015-07-31
DOP2017000030A (es) 2017-02-28
EA201690787A1 (ru) 2017-02-28
AU2016200538B2 (en) 2017-08-31
KR20130143629A (ko) 2013-12-31
JP2017008072A (ja) 2017-01-12
MX2013007319A (es) 2013-07-22
EP3176172B1 (en) 2020-01-29
CL2013001849A1 (es) 2013-12-20
CN103380133B (zh) 2016-06-29
TWI618700B (zh) 2018-03-21
AU2011345389A1 (en) 2013-08-01
EA032687B1 (ru) 2019-07-31
US20150133471A1 (en) 2015-05-14
TWI633092B (zh) 2018-08-21
US20130210837A1 (en) 2013-08-15
SA114360153B1 (ar) 2015-11-29
AU2017261475A1 (en) 2017-11-30
EA025746B1 (ru) 2017-01-30
TW201302713A (zh) 2013-01-16
KR101916975B1 (ko) 2018-11-08
EP3176172A1 (en) 2017-06-07
ZA201305495B (en) 2016-07-27
CO6781485A2 (es) 2013-10-31
US9248129B2 (en) 2016-02-02
AU2016200538A1 (en) 2016-02-18
TW201716386A (zh) 2017-05-16
EA025746B9 (ru) 2017-06-30
ECSP13012708A (es) 2013-08-30
SG191127A1 (en) 2013-07-31
PE20141191A1 (es) 2014-09-21
US8415483B2 (en) 2013-04-09
BR112013016030B1 (pt) 2022-03-29
CN106008355A (zh) 2016-10-12
NZ709235A (en) 2016-11-25
BR112013016030A2 (pt) 2018-07-24
CA2822378C (en) 2020-01-14
ES2626727T3 (es) 2017-07-25
DOP2013000147A (es) 2013-10-15
AR084553A1 (es) 2013-05-22
PT2655378T (pt) 2017-05-29
SA111330107B1 (ar) 2015-03-26
CA2822378A1 (en) 2012-06-28
CY1119211T1 (el) 2018-02-14
US8865911B2 (en) 2014-10-21
MX342477B (es) 2016-09-30
CN103380133A (zh) 2013-10-30
NI201300055A (es) 2014-03-07
PL2655378T3 (pl) 2017-09-29
DOP2016000191A (es) 2016-09-15
US10231967B2 (en) 2019-03-19
US20160184303A1 (en) 2016-06-30
EA201390830A1 (ru) 2013-12-30
JP6180325B2 (ja) 2017-08-16
UY33829A (es) 2012-07-31
JP6333317B2 (ja) 2018-05-30
AU2011345389B2 (en) 2015-10-29
CR20130308A (es) 2014-02-13
EP2655378B1 (en) 2017-03-01
GT201300165A (es) 2015-02-11
ME02728B (me) 2017-10-20
ES2780928T3 (es) 2020-08-27
US9918985B2 (en) 2018-03-20
HRP20170723T1 (hr) 2017-07-28
DK2655378T3 (en) 2017-06-06
EP2655378A4 (en) 2014-07-09
US20170319578A1 (en) 2017-11-09
MY178156A (en) 2020-10-06
SI2655378T1 (sl) 2017-06-30
SG10201602241SA (en) 2016-04-28
JP2018083840A (ja) 2018-05-31
PE20171342A1 (es) 2017-09-13

Similar Documents

Publication Publication Date Title
DK2655378T3 (en) RELATIONSHIPS AND THEIR USE AS BACE INHIBITORS
DK2748149T5 (en) Pyridazinone compounds and their use as DAAO inhibitors
KR20100055456A (ko) 다환식 화합물
TW201835072A (zh) 新穎cyp11a1抑制劑
KR20140022840A (ko) 당뇨병을 치료하기 위한 호르몬 감수성 리파제 저해제로서의 2급-하이드록시사이클로헥실 유도체
WO2020048830A1 (en) 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds